Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to establish an individualized first-line treatment incorporating
checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.